OTC Profiler is promoting PTLF for: Tuesday 2/21/2017
Lets see what happens.
About PetLife Pharmaceuticals, Inc.
PetLife Pharmaceuticals, Inc. (PetLife) has developed and is launching a new generation of potentiated veterinary cancer medications and nutraceuticals, under its new tradename VitalzulTM, based on the same patented formula "Escozine" and production processes that have been scientifically proven as an effective treatment for cancer in humans for years. Escozine (for humans) is currently sold as either a nutraceutical or prescription drug in 40 countries including the US.
PTLF Operates In the Booming $62B Pet Health Industry!
PTLF is poised to change the paradigm of treatment in veterinary oncology. It is reported that over 50% of dogs and cats living past the age of 10 develop cancer. Last year in the U.S. approximately 13 million families had to face this diagnosis in their beloved companion animals. Our all natural "Vitalzul for Pets™ has a strong scientific basis for the treatment of cancer and offers an alternative to standard chemotherapy, surgery and other invasive treatment that are often as toxic as the cancer itself. PetLife's mission is to provide an affordable solution that also avoids the unfortunate and often deadly side effects of traditional treatment.
PetLife Pharmaceuticals is introducing a new break through pet cancer drug that is anticipated to begin FDA trials this summer. The drug is an organic-all natural compound. The FDA trials are estimated to take no longer than 18-24 months.
With pets living longer than ever, cancer is becoming a serious problem.
Cancer is the # 1 disease related cause of death for dogs in the U.S.
Cancer accounts for almost 50% of deaths in pets older than 10 years Average costs to treat lymphoma in pets is $2,000-most owners will rather watch their pets die than pursue treatment 1 in 4 dogs and 1 in 5 cats will develop cancer in their lifetime.
Dogs get cancer at about the same rate as humans
PetLife Pharmaceuticals, Inc. (PetLife) has developed and is launching a new generation of HP (high potency) veterinary cancer medications and nutraceuticals, based on the same patented formula "Escozine" and production processes that have been scientifically proven as an effective treatment for cancer in humans for years. Escozine (for humans) is currently sold as either a nutraceutical or prescription drug in 40 countries including the US.
Given the histology (the similarity of the cellular biology) between humans and dogs and cats and the growing body of new preclinical research (UCSD) establishing the effectiveness of Escozine for the treatment of animals, PetLife has licensed the worldwide rights to formulate, package and market a new product line, "Escozine for PetsTM."
The Company's products have been demonstrated as a preventative and a treatment of cancer, and to dramatically improve the quality of life, and extend the longevity of pets with cancer -- without the painful, debilitating side effects of toxic, conventional chemotherapy.
Investor Highlights
PetLife Pharmaceuticals has licensed the worldwide rights to formulate, package and market a new product line, "Escozine for Pets™.
In the US alone, consumer spending on domestic companion animals reached over $60 billion in 2015 with over $29 billion spent on veterinary care and medications.
62% of American households include at least one pet.
PetLife Pharmaceuticals Just Announced Huge News of New Chairman of Product Development and Advisory Board World Renowned Veterinary Nutritionist Dr. R. Geoffrey Broderick
Virtually undiscovered company with ground floor opportunity with a unique product that has the potential to prevent and treat cancer and to dramatically improve quality of life and extend the longevity of pets with cancer -- without the harmful side effects of conventional chemotherapy and other traditional treatment programs.
PTLF is one exciting stock with a powerhouse management team!
PTLF has taken huge steps forward recently, placing the Company in an excellent position for growth.
They just announced HUGE News that they have appointed World Renowned Dr. R. Geoffrey Broderick as the Chairman of Product Development and Advisory Board all of which indicate the Company's Huge Growth potential!
Dr. Broderick, one of the world's most famous veterinarians, comes to PetLife Pharmaceuticals with an intricate knowledge of the pet industry, he is a practicing veterinarian with over 48 years' experience as an international expert, and is also a professional developer of organic pet food, pet supplements, and other pet products, including the first natural pet food, the first snack for senior dogs, the first dietary formula, and the first antioxidant supplement.
Besides these preventative revolutionary inventions, he also prevailed in his veterinary career with many awards and other accreditations. He was the first in history to dissolve urinary stones without antibiotics, for which he is the recipient (and the youngest to ever receive) the Award by the Committee for World Health, which was presented on the 50th anniversary for the discovery of Vitamin C (in Palm Springs CA, 1978). In fact, this revolutionary work was eventually incorporated in his subsequently developed Cornucopia Natural Pet Products in order to provide the proper PH of urine to prevent struvite (triple phosphate) urinary stones from happening in the first place.
Bottom Line...
PTLF is a unique opportunity in an expanding $62 Billion Dollar Industry and we think you should take a serious look at this company!
Wall Street is about to Show Major Interest in PTLF!
Remember PTLF is no stranger to big moves, back in July it ran from .17 cents to 1.00. We have seen a few pull backs since followed by big runs, I now believe its setting up for another Monster Run.
If you missed the big moves on my some of my recent big picks, YOU better get busy now and research PTLF and have it pulled up early Tuesday morning.
Best Regards,
The OTCprofiler Team
